


WHAT IS CLAIMED IS:

2 1.. A pharmaceutical composition for the treatment of a malignant
3 disease or condition in a mammal, the composition comprising a
4 pharmaceutically acceptable excipient and a therapeutically effective dose of a
5 compound of the formula




13 where R_1 is independently H or lower alkyl of 1 to 6 carbons;
14 R_2 and R_3 are independently H, lower alkyl of 1 to 6 carbons, F, Cl,
15 Br, I, alkoxy of 1 to 6 carbons, or fluoroalkoxy of 1 to 6 carbons;
16 m is an integer 0 to 3;
17 o is an integer 0 to 4;
18 n is 0-5;
19 Y is phenyl, naphthyl, or a heteroaryl group selected from a group
20 consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl;
21 oxazolyl, thiazolyl, or imidazolyl, and
22 B is COOH, a pharmaceutically acceptable salt thereof, $CONR_6R_7$ or
23 $COOR_8$ where R_6 and R_7 independently are hydrogen or an alkyl group of 1
24 to 6 carbons and R_8 is alkyl of 1 to 6 carbons,
25 said composition being adapted to be used in combination with another
26 chemotherapeutic agent effective for the treatment of the malignant disease or
27 condition of the mammal.

1 2. A pharmaceutical composition in accordance with Claim 1 wherein
2 the chemotherapeutic agent effective for the treatment of the malignant
3 disease or condition of the mammal is interferon.

4 3. A pharmaceutical composition in accordance with Claim 2 adapted
5 for the treatment of breast cancer.

6 4. A pharmaceutical composition in accordance with Claim 2 adapted
7 for the treatment of leukemia.

8 5. A pharmaceutical composition in accordance with Claim 1 wherein
9 the compound has the formula



20 6. A pharmaceutical composition in accordance with Claim 5 wherein
21 the chemotherapeutic agent effective for the treatment of the malignant
22 disease or condition of the mammal is interferon.

23 7. A pharmaceutical composition in accordance with Claim 6 adapted
24 for the treatment of breast cancer.

25 8. A pharmaceutical composition in accordance with Claim 5 adapted
26 for the treatment of leukemia.

27 9. A pharmaceutical composition in accordance with Claim 1 wherein
28 the compound has the formula

1

2

3

4

5

6

7

8 where R_8 is H, alkyl of 1 to 3 carbons, or a pharmaceutically acceptable
9 salt of said compound.

10 10. A pharmaceutical composition in accordance with Claim 9 wherein
11 the chemotherapeutic agent effective for the treatment of the malignant
12 disease or condition of the mammal is interferon.

13 11. A pharmaceutical composition in accordance with Claim 10
14 adapted for the treatment of breast cancer.

15 12. A pharmaceutical composition in accordance with Claim 10
16 adapted for the treatment of leukemia.

17 13. A pharmaceutical composition in accordance with Claim 9 where
18 R_8 is ethyl.

19 ~~Sub A~~ 14. A method of treating a malignant disease or condition in a
20 mammal in need of such treatment, the method comprising the steps of:
21 administering to said mammal a pharmaceutical composition
22 comprising a pharmaceutically acceptable excipient and a therapeutically
23 effective dose of a compound of the formula


24

25

26

27

28



Sub A3
cont'd

1 where R_1 is independently H or lower alkyl of 1 to 6 carbons;

2 R_2 and R_3 are independently H, lower alkyl of 1 to 6 carbons, F, Cl,

3 Br, I, alkoxy of 1 to 6 carbons, or fluoroalkoxy of 1 to 6 carbons;

4 m is an integer 0 to 3;

5 o is an integer 0 to 4;

6 n is 0-5;

7 Y is phenyl, naphthyl, or a heteroaryl group selected from a group

8 consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl;

9 oxazolyl, thiazolyl, or imidazolyl;

10 B is COOH, a pharmaceutically acceptable salt thereof, $CONR_6R_7$, or

11 $COOR_8$ where R_6 and R_7 independently are hydrogen or an alkyl group of 1

12 to 6 carbons and R_8 is alkyl of 1 to 6 carbons, and

13 co-administering to said mammal with said compound another

14 chemotherapeutic agent effective for the treatment of the malignant disease or

15 condition of the mammal.

16 15. A method in accordance with Claim 14 where the

17 chemotherapeutic agent is interferon.

18 16. A method in accordance with Claim 15 where the

19 chemotherapeutic agent is human recombinant interferon α , human

20 recombinant interferon β , or human recombinant interferon γ .

21 17. A method in accordance with Claim 16 where the malignant

22 disease or condition treated is breast cancer or leukemia.

23 18. A method in accordance with Claim 17 where the malignant

24 disease or condition treated is acute myeloid leukemia.

25 19. A method in accordance with Claim 14 wherein the compound has

26 the formula

1

2

3

4

5

6

7

8

9 where \mathbf{R}_1 is H or methyl, \mathbf{R}_3 is H or methyl, and \mathbf{R}^*_8 is H, or lower
10 alkyl of 1 to 3 carbons, or a pharmaceutically acceptable salt of said
11 compound.

12 **20.** A method in accordance with Claim 19 where the
13 chemotherapeutic agent is interferon.

14 **21.** A method in accordance with Claim 20 where the
15 chemotherapeutic agent is human recombinant interferon α , human
16 recombinant interferon β , or human recombinant interferon γ .

17 **22.** A method in accordance with Claim 21 where the malignant
18 disease or condition treated is breast cancer or leukemia.

19 **23.** A method in accordance with Claim 21 where the malignant
20 disease or condition treated is acute myeloid leukemia.

21 **24.** A method in accordance with Claim 14 wherein the compound has
22 the formula

23



24

25

26

27

28



1 where R_8 is H, alkyl of 1 to 3 carbons, or a pharmaceutically acceptable
2 salt of said compound.

3 25. A method in accordance with Claim 24 where R_8 is ethyl.

4 26. A method in accordance with Claim 25 where the
5 chemotherapeutic agent is interferon.

6 27. A method in accordance with Claim 26 where the
7 chemotherapeutic agent is human recombinant interferon α , human
8 recombinant interferon β , or human recombinant interferon γ .

9 28. A method in accordance with Claim 27 where the malignant
10 disease or condition treated is breast cancer or leukemia.

11 29. A method in accordance with Claim 27 where the malignant
12 disease or condition treated is acute myeloid leukemia.

13 30. A method in accordance with any of the Claims 24 through 29
14 wherein a daily dose of approximately 50 mg to 500 mg of the compound is
15 administered to the mammal.

Add B37